BDH Industries Ltd
Incorporated in 1935, BDH Industries Ltd manufactures therapeutic formulations covering wide range of pharmaceuticals[1]
- Market Cap ₹ 214 Cr.
- Current Price ₹ 372
- High / Low ₹ 524 / 241
- Stock P/E 20.5
- Book Value ₹ 123
- Dividend Yield 1.21 %
- ROCE 17.8 %
- ROE 14.2 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
- Company has been maintaining a healthy dividend payout of 27.4%
Cons
- The company has delivered a poor sales growth of 2.26% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 42 | 44 | 46 | 43 | 41 | 52 | 59 | 57 | 69 | 74 | 86 | 67 | 85 | |
| 39 | 40 | 42 | 38 | 36 | 45 | 51 | 49 | 60 | 64 | 73 | 55 | 72 | |
| Operating Profit | 4 | 4 | 4 | 5 | 5 | 7 | 9 | 9 | 9 | 11 | 12 | 12 | 13 |
| OPM % | 9% | 9% | 9% | 11% | 13% | 14% | 15% | 15% | 13% | 15% | 14% | 17% | 15% |
| 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | |
| Interest | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 3 | 4 | 5 | 5 | 5 | 7 | 8 | 9 | 10 | 11 | 13 | 12 | 14 |
| Tax % | 33% | 32% | 33% | 33% | 27% | 26% | 27% | 27% | 24% | 26% | 25% | 26% | |
| 2 | 3 | 3 | 3 | 4 | 5 | 6 | 6 | 7 | 8 | 10 | 9 | 10 | |
| EPS in Rs | 3.99 | 4.46 | 5.61 | 5.80 | 6.53 | 8.39 | 10.32 | 11.05 | 12.54 | 14.24 | 17.14 | 16.10 | 18.11 |
| Dividend Payout % | 31% | 39% | 37% | 36% | 36% | 34% | 25% | 28% | 29% | 28% | 26% | 28% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 2% |
| 3 Years: | -1% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 9% |
| 3 Years: | 10% |
| TTM: | 7% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 30% |
| 3 Years: | 41% |
| 1 Year: | 37% |
| Return on Equity | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 15% |
| 3 Years: | 16% |
| Last Year: | 14% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | 17 | 18 | 21 | 23 | 25 | 28 | 32 | 37 | 43 | 49 | 56 | 63 | 65 |
| 11 | 9 | 9 | 8 | 8 | 13 | 9 | 9 | 2 | 5 | 9 | 1 | 0 | |
| 14 | 19 | 15 | 17 | 18 | 18 | 18 | 19 | 18 | 20 | 23 | 17 | 18 | |
| Total Liabilities | 48 | 52 | 52 | 54 | 57 | 66 | 65 | 71 | 69 | 80 | 93 | 87 | 89 |
| 15 | 13 | 13 | 23 | 23 | 22 | 21 | 20 | 20 | 19 | 20 | 20 | 19 | |
| CWIP | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 33 | 38 | 35 | 31 | 34 | 44 | 44 | 51 | 49 | 61 | 73 | 67 | 69 | |
| Total Assets | 48 | 52 | 52 | 54 | 57 | 66 | 65 | 71 | 69 | 80 | 93 | 87 | 89 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 | 6 | 4 | 7 | -0 | -4 | 11 | 1 | 3 | 6 | -2 | 15 | |
| -0 | -0 | -5 | -5 | 0 | 1 | 1 | 1 | 1 | 0 | -0 | 2 | |
| 3 | -3 | -1 | -3 | -3 | 3 | -6 | -2 | -8 | 0 | 1 | -10 | |
| Net Cash Flow | 6 | 3 | -1 | -1 | -2 | 0 | 6 | -0 | -4 | 7 | -1 | 6 |
| Free Cash Flow | 3 | 6 | -0 | 1 | -1 | -4 | 11 | 1 | 4 | 6 | -4 | 15 |
| CFO/OP | 137% | 198% | 146% | 186% | 21% | -24% | 153% | 35% | 64% | 82% | 11% | 153% |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 68 | 81 | 64 | 67 | 63 | 89 | 68 | 96 | 76 | 82 | 121 | 78 |
| Inventory Days | 65 | 71 | 61 | 39 | 95 | 89 | 51 | 53 | 50 | 53 | 30 | 65 |
| Days Payable | 144 | 201 | 162 | 192 | 244 | 188 | 158 | 171 | 123 | 139 | 128 | 134 |
| Cash Conversion Cycle | -11 | -49 | -37 | -85 | -85 | -10 | -39 | -21 | 4 | -5 | 23 | 9 |
| Working Capital Days | -74 | -76 | -72 | -90 | -60 | -29 | -31 | 6 | 56 | 49 | 71 | 102 |
| ROCE % | 13% | 13% | 15% | 14% | 14% | 16% | 19% | 18% | 18% | 20% | 21% | 18% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Domestic Revenue ₹ In Lakhs |
|
|||||||||||
| Export Revenue ₹ In Lakhs |
||||||||||||
| Number of Employees Number |
||||||||||||
| Installed Wind Power Capacity MW |
||||||||||||
| Electrical Energy Generated (Wind) kWh |
||||||||||||
| Gross Current Asset (GCA) Days Days |
||||||||||||
| R&D Expenditure (Percentage of Turnover) % |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Intimation To Shareholders Holding Equity Shares In Physical Form
1d - Intimation to physical shareholders to furnish KYC details to RTA.
- Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 2d
- Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 2d
-
Board Meeting Intimation for Considering And Approving The Audited Standalone Financial Results Of The Company For The Fourth Quarter And Year Ended On 31St March 2026 And Recommendation Of Dividend, If Any For The Financial Year Ended On 31St March 2026.
12 May - Board meets on 21 May 2026 to approve Q4/FY26 audited results and consider dividend.
- Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011 24 Apr
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
BDHIL is a full-service Contract Manufacturing Organization for production of Pharmaceutical, Oncological Products and associated packaging services. It is an exporter and manufacturer of therapeutic formulations covering a wide range of pharmaceuticals